Overview

This trial is active, not recruiting.

Condition pectus excavatum
Treatments patient controlled analgesia, continuous thoracic epidural infusions, continuous paravertebral blockade
Sponsor Ralph Beltran
Start date November 2013
End date December 2016
Trial size 32 participants
Trial identifier NCT02009267, IRB13-00702

Summary

A retrospective chart review study analyzing the benefits of patient controlled analgesia, thoracic epidural analgesia, and paravertebral nerve block catheters in patients having surgical repair of pectus excavatum using the Nuss procedure.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective
Arm
Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
patient controlled analgesia
A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
continuous thoracic epidural infusions
Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation—including the sensation of pain—by blocking the transmission of signals through nerve fibers in or near the spinal cord.
Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
continuous paravertebral blockade
Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.

Primary Outcomes

Measure
Total morphine dose
time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days

Secondary Outcomes

Measure
Pain score
time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days
Length of hospitalization
time frame: Within the first week after surgery.
Nausea and vomiting
time frame: 0-48 hrs. post-op

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients undergoing the NUSS procedure since the beginning of 2011 to Sept. 30th, 2013. Exclusion Criteria:

Additional Information

Principal investigator Beltran Ralph, MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Nationwide Children's Hospital.